Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J. Rizk DV, et al. Among authors: barratt j. Kidney Int Rep. 2023 Feb 9;8(5):968-979. doi: 10.1016/j.ekir.2023.01.041. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180505 Free PMC article.
Treatment of IgA nephropathy.
Barratt J, Feehally J. Barratt J, et al. Kidney Int. 2006 Jun;69(11):1934-8. doi: 10.1038/sj.ki.5000419. Kidney Int. 2006. PMID: 16641928 Free article. Review.
The MEST score provides earlier risk prediction in lgA nephropathy.
Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. Barbour SJ, et al. Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322. Kidney Int. 2016. PMID: 26759049 Free article.
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. Among authors: barratt j. Kidney Int. 2020 Oct;98(4):1009-1019. doi: 10.1016/j.kint.2020.04.042. Epub 2020 May 25. Kidney Int. 2020. PMID: 32464215 Free article.
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D; International IgA Nephropathy Network; International IgA Nephropathy Network Investigators. Canney M, et al. J Am Soc Nephrol. 2021 Feb;32(2):436-447. doi: 10.1681/ASN.2020030349. Epub 2020 Dec 23. J Am Soc Nephrol. 2021. PMID: 33514642 Free PMC article.
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Kidney Int. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560136 Free article. Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Among authors: barratt j. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
The authors reply.
Barratt J, Rovin BH; NefIgArd Investigators. Barratt J, et al. Kidney Int. 2023 May;103(5):994-995. doi: 10.1016/j.kint.2023.02.014. Kidney Int. 2023. PMID: 37085260 No abstract available.
479 results